title: A meta-analysis of methylprednisolone in recovery from multiple sclerosis exacerbations.
abstract: Despite recent advances in multiple sclerosis treatment, patients experience relapses for which standard treatment remains glucocorticosteroids (GCS). However, there is limited information comparing doses or routes of administration for different GCS types or the benefit of GCS compared to natural recovery. Currently, high dose (HD) methylprednisolone (MP) is the preferred therapy. We conducted meta-analyses of published studies assessing MP at different doses and in comparison to other steroid products or no treatment. Relevant studies were identified through predetermined processes and five articles met the inclusion criteria. Three studies compared HD MP to placebo; two studies compared the effect of HD MP and low dose (LD) MP; only one accepted report compared HD MP to another GCS. This report could not be included in a meta-analysis. The meta-analysis of HD MP vsplacebo studies indicated a mean treatment difference of 0.76 in Expanded Disability Status Score (EDSS) changes from baseline. The meta-analysis of HD and LD MP demonstrated no difference in EDSS change. Despite these rather obvious findings, these meta-analyses have been valuable in identifying further research questions. We recommend studies to determine optimum benefit related to dosage, timing for starting therapy and the most appropriate GCS type. Given the advances in MS therapeutics, these studies will have to include patients on additional disease modifying therapy. Multiple Sclerosis (2000) 6 267 - 273
authors.affiliation: I.H. Page Center for Health Outcomes Research, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA.
authors.forename: D M
authors.initials: DM
authors.lastname: Miller
authors.forename: B
authors.initials: B
authors.lastname: Weinstock-Guttman
authors.forename: F
authors.initials: F
authors.lastname: Béthoux
authors.forename: J C
authors.initials: JC
authors.lastname: Lee
authors.forename: G
authors.initials: G
authors.lastname: Beck
authors.forename: V
authors.initials: V
authors.lastname: Block
authors.forename: L
authors.initials: L
authors.lastname: Durelli
authors.forename: L
authors.initials: L
authors.lastname: LaMantia
authors.forename: D
authors.initials: D
authors.lastname: Barnes
authors.forename: F
authors.initials: F
authors.lastname: Sellebjerg
authors.forename: R A
authors.initials: RA
authors.lastname: Rudick
mesh_terms: D004185:Disability Evaluation; D004305:Dose-Response Relationship, Drug; D006801:Humans; D008775:Methylprednisolone / Q000008:administration & dosage / Q000627:therapeutic use*; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000503:physiopathology*; D018696:Neuroprotective Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D010919:Placebos
chemical_list: D018696:Neuroprotective Agents; D010919:Placebos; D008775:Methylprednisolone